Beijing Hotgen Biotech Co., Ltd. (688068.SS)
CNY 120.74
(5.36%)
CNY 120.74
(5.36%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 541.25 Million CNY | -84.78% |
| 2022 | 3.55 Billion CNY | -33.76% |
| 2021 | 5.36 Billion CNY | 945.54% |
| 2020 | 513.53 Million CNY | 144.06% |
| 2019 | 210.41 Million CNY | 12.45% |
| 2018 | 187.12 Million CNY | 31.69% |
| 2017 | 142.08 Million CNY | 16.28% |
| 2016 | 122.19 Million CNY | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 136.24 Million CNY | 2.69% |
| 2024 Q2 | 132.68 Million CNY | 14.26% |
| 2024 Q1 | 116.12 Million CNY | -13.49% |
| 2023 Q1 | 202.93 Million CNY | -62.92% |
| 2023 FY | 541.14 Million CNY | -84.78% |
| 2023 Q4 | 134.22 Million CNY | 34.35% |
| 2023 Q3 | 99.9 Million CNY | -4.0% |
| 2023 Q2 | 104.06 Million CNY | -48.72% |
| 2022 Q1 | 1.36 Billion CNY | -13.3% |
| 2022 Q2 | 681.33 Million CNY | -50.06% |
| 2022 Q4 | 547.37 Million CNY | -43.19% |
| 2022 Q3 | 963.49 Million CNY | 41.41% |
| 2022 FY | 3.55 Billion CNY | -33.76% |
| 2021 Q3 | 195.85 Million CNY | -91.74% |
| 2021 Q2 | 2.37 Billion CNY | 93.24% |
| 2021 Q1 | 1.22 Billion CNY | 233.56% |
| 2021 FY | 5.36 Billion CNY | 945.54% |
| 2021 Q4 | 1.57 Billion CNY | 703.48% |
| 2020 Q4 | 368.02 Million CNY | 561.75% |
| 2020 FY | 513.53 Million CNY | 144.06% |
| 2020 Q1 | 38.37 Million CNY | -47.12% |
| 2020 Q3 | 55.61 Million CNY | 7.93% |
| 2020 Q2 | 51.52 Million CNY | 34.29% |
| 2019 FY | 210.41 Million CNY | 12.45% |
| 2019 Q3 | 43.88 Million CNY | -22.93% |
| 2019 Q2 | 56.94 Million CNY | 53.8% |
| 2019 Q1 | 37.02 Million CNY | -43.35% |
| 2019 Q4 | 72.56 Million CNY | 65.35% |
| 2018 Q3 | 39.63 Million CNY | 0.0% |
| 2018 FY | 187.12 Million CNY | 31.69% |
| 2018 Q4 | 65.35 Million CNY | 64.89% |
| 2018 Q1 | 33.68 Million CNY | 0.0% |
| 2017 FY | 142.08 Million CNY | 16.28% |
| 2016 FY | 122.19 Million CNY | 0.0% |